Effect of oxcarbazepine pretreatment on convulsive activity and brain damage induced by kainic acid administration in rats.
Temporal lobe epilepsy is one of the most common types of epilepsy. Progress in the understanding and treatment of this type of epilepsy would be greatly facilitated by the availability of an animal model, which reproduced the behavioral and electrographic features of this condition. In this context, kainic acid (KA, 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine) administration causes a syndrome characterized by an acute status epilepticus and subsequent brain damage similar to that in temporal lobe epilepsy of humans. The aim of the present study was to investigate whether oxcarbazepine (10,11-dihydro-10-oxo-5 H -dibenz(b,f)azepine-5-carboxamide), an antiepileptic drug, protects against both epileptic activity and brain damage induced by KA administration. Chronically implanted adult male Wistar rats were polygraphically recorded during 10 continuous hours under 4 different conditions: a) control, b) after KA administration alone, c) after KA administration in oxcarbazepine pretreated animals and d) after the administration of oxcarbazepine alone. Animals treated with KA alone presented behavioral and electrophysiological convulsive activity as well as brain damage. Latency of seizure installation was lengthened significantly and convulsive activity was slightly reduced, however, brain damage was still present in oxcarbazepine pretreated animals. Administration of oxcarbazepine alone induced a hypnotic behavior and brain damage was also present.
Facultad de Psicología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico. Electronic address: fayala@servidor.unam.mx.
Fructuoso
F
Ayala-Guerrero
Facultad de Psicología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico.
Graciela
G
Mexicano
Facultad de Psicología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico.
Efraín
E
Campos-Sepúlveda
Instituto Nacional de Pediatría México, Mexico.
Rosa María
RM
Romero
Instituto Nacional de Pediatría México, Mexico.
Rafael
R
Reynoso-Robles
Instituto Nacional de Pediatría México, Mexico.
Angélica
A
González-Maciel
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000473:pathology*; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004195:Disease Models, Animal; D004827:Epilepsy / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology*; D018690:Excitatory Amino Acid Agonists / Q000633:toxicity; D007608:Kainic Acid / Q000633:toxicity; D008297:Male; D000078330:Oxcarbazepine; D051381:Rats; D017208:Rats, Wistar
D000927:Anticonvulsants; D018690:Excitatory Amino Acid Agonists; D002220:Carbamazepine; D007608:Kainic Acid; D000078330:Oxcarbazepine